Background {#Sec1}
==========

More than two million transrectal ultrasound guided prostate biopsies (TRUSP) are performed in the US and Europe annually \[[@CR1], [@CR2]\]. Infectious complications range from uncomplicated urinary tract infections (UTIs) to prostatitis to sepsis and death \[[@CR3]\]. Empiric antimicrobial prophylaxis reduced the risk of infectious complications \[[@CR4]\] but, with increasing resistance, infections after biopsy have risen \[[@CR1], [@CR5]--[@CR9]\] and are most commonly fluoroquinolone (FQ)-resistant (R) gram-negative bacteria (GNB) \[[@CR10]\].

Two primary prophylaxis strategies have emerged to prevent post-biopsy infections, a targeted or an empiric approach \[[@CR7], [@CR11]--[@CR13]\]. The targeted approach involves obtaining a pre-biopsy rectal swab culture and choosing an antimicrobial agent based on culture results. The empiric approach is frequently based on local antibiograms \[[@CR7], [@CR12], [@CR14]--[@CR16]\]. Both approaches can be augmented by adding an antimicrobial agent to a fluoroquinolone or combination non-quinolone based regimen. To date, although studies have shown significant reduction in infectious complications, these studies may have been subject to underreporting because they were retrospective \[[@CR5], [@CR12], [@CR14], [@CR15]\], did not use phone contact for follow-up \[[@CR7], [@CR12]--[@CR16]\], did not report non-hospitalized infections \[[@CR7], [@CR11], [@CR12]\], and followed patients for less than 30 days \[[@CR11], [@CR16]\]. Additionally, the augmented approach introduces the concern for driving further antimicrobial resistance \[[@CR17]\].

In our study, we prospectively evaluated patients by phone interview at 7 and 30 days to evaluate the rate of all post-biopsy infections in our patients treated with targeted prophylaxis based on rectal swab culture. Targeted antimicrobial prophylaxis achieved a low rate of infectious complications, limited morbidity and no sequelae in patients with either ciprofloxacin- susceptible or -resistant gram-negative rectal flora. These results suggest that this individualized method of prophylaxis may be widely applied.

Methods {#Sec2}
=======

Study setting and design {#Sec3}
------------------------

The study was conducted in the Northwestern University (NU) Feinberg School of Medicine Department of Urology at Northwestern Memorial Hospital between November 1, 2012 and March 31, 2015. This prospective, non-randomized cohort trial evaluated the efficacy of targeted pre-procedural antimicrobial prophylaxis for TRUSP and tested the hypothesis that infectious complication rates for targeted prophylaxis in patients with ciprofloxacin-susceptible compared to ciprofloxacin-resistant gram-negative bacteria (CS-GNB and CR-GNB, respectively) rectal flora would be equivalent. The Institutional Review Board of NU approved this study.

Recruitment and eligibility criteria {#Sec4}
------------------------------------

Eligible patients were men 18 years or older selected to undergo TRUSP to evaluate for prostate cancer. Patients were excluded from the study if (1) they did not complete or withdrew informed consent; (2) their rectal swab cultures were CS-GNB but they did not receive ciprofloxacin as pre-procedure prophylaxis (i.e. ciprofloxacin-allergic patients); (3) their rectal swab cultures showed CR-GNB but they received ciprofloxacin; or (4) they did not complete the pre-biopsy questionnaire or the two post-biopsy phone screening evaluations. Of the 510 study participants, 26, who fulfilled eligibility criteria but received augmented prophylaxis (24 empiric, 2 directed) at the discretion of the treating physician, were evaluated in a separate intention-to-treat (ITT) analysis.

Clinical specimen processing {#Sec5}
----------------------------

After completing a pre-biopsy questionnaire (Additional file [1](#MOESM1){ref-type="media"}) to record demographics and to evaluate risk factors for infection, all subjects had rectal swab cultures obtained no more than 30 days prior to the TRUSP (Additional file [2](#MOESM2){ref-type="media"}). Swabs were cultured on blood agar and on MacConkey agar supplemented with 1 μg/ml ciprofloxacin (Thermo Scientific™ Remel™, Waltham, MA, USA). Quality control (QC) was performed on each new lot and shipment of MacConkey agar according to manufacturer's instructions \[[@CR18]\]. The following QC strains were utilized: *Staphylococcus aureus* ATCC® 25,923; *Pseudomonas aeruginosa* ATCC® 27,853; *Escherichia coli* ATCC® 25,922; and *Escherichia coli strain* \#OC110. The plates were placed in a CO~2~ incubator (35° to 37 °C) and read at 36--48 h.

Bacterial species identification and antimicrobial susceptibility testing {#Sec6}
-------------------------------------------------------------------------

Blood agar plates without growth indicated inadequate specimen collections. Specimens with growth on blood agar only were considered to contain CS-GNR. Specimens with growth of gram-negative rods (GNRs) on blood and supplemented MacConkey agar underwent organism identification and antimicrobial susceptibility testing using an automated microbial system (Vitek® 2, Biomérieux, Durham, NC, USA) using the AST-GN47 cards. Antimicrobial susceptibilities were reported according to Clinical Laboratory Standards Institute (CLSI) guidelines \[[@CR19]\].

Selection of antimicrobial prophylaxis {#Sec7}
--------------------------------------

Prophylactic antimicrobial agents were selected using a pre-determined protocol (Additional file [3](#MOESM3){ref-type="media"}). Patients with CS-GNR received ciprofloxacin 500 mg orally 2 h before TRUSP and 500 mg orally 12 h later. Subjects harboring CR-GNB received an antimicrobial agent based on the AUA guidelines (Additional file [3](#MOESM3){ref-type="media"}). Selection of the narrowest spectrum agent available was encouraged. Twenty-six patients (24 CS, 2 CR) received targeted prophylaxis augmented by another antimicrobial at the discretion of the treating physician based on the patient's clinical status.

Clinical evaluation {#Sec8}
-------------------

The data were derived from the pre-biopsy questionnaire and electronic medical record review. Charlson score was calculated by ICD-9 codes \[[@CR20]\]. Immediately prior to the biopsy, enema and antimicrobial prophylaxis, including drug, dose, and timing, were confirmed. Phone screening at days 7 and 30 following TRUSP determined whether the patients experienced infectious complications (Additional file [4](#MOESM4){ref-type="media"}) or adverse drug reactions based on pre-determined criteria.

Outcomes and definitions {#Sec9}
------------------------

The primary outcome was to compare the rate of infection following TRUSP in subjects with and without CR-GNB. Secondary objectives included determination of risk factors for infection and antimicrobial resistance traits of rectal swab isolates. Infectious complications were clinically defined as 1) uncomplicated urinary tract infection (UTI): dysuria, urgency, frequency or hematuria without fever and with or without pyuria (\> 5 white blood cells per high-powered field or positive leukocyte esterase on urine dipstick) or bacteriuria (≥ 10^5^ colony-forming units/mL); 2) complicated UTI: fever, flank pain, nausea or vomiting with or without pyuria and bacteriuria; 3) urosepsis: criteria for sepsis, severe sepsis, and septic shock \[[@CR21]\] were combined and categorized as urosepsis.

Statistical analysis {#Sec10}
--------------------

Analyses were performed with SAS version 9.3 (SAS Institute Inc., Cary, NC) and R version 3.3 (R Foundation for Statistical Computing, Vienna, Austria). Categorical variables were described by percentages and compared using Chi-square or Fisher exact tests as appropriate. Continuous variables were described by means and evaluated using Student t-test. A *p*-value \<0.05 was considered statistically significant. Our initial goal was to enroll 1700 patients, and have enough patients in each group to obtain a 95% confidence interval for the difference in the complication rates between the two groups with a margin of error of, at most, 2%.

Results {#Sec11}
=======

Clinical characteristics {#Sec12}
------------------------

Five hundred ten (90.6%) patients were included in the analysis (Fig. [1](#Fig1){ref-type="fig"}). 24 patients underwent more than one biopsy. Outcomes of all were recorded, but only infectious outcomes from the first biopsy were included. The time between rectal swab culture and TRUSP ranged from 7 to 30 days. Of the 510 patients, 26 received a second prophylactic antimicrobial agent at the discretion of the treating physician based on the patient's clinical status; therefore, 510 patients were included in the ITT analysis and 484 in the per-protocol analysis.Fig. 1Study Subjects. TRUSP, Transrectal ultrasound guided prostate biopsy

Patient demographics and clinical characteristics of the 510 ITT patients stratified by ciprofloxacin susceptibility status are listed in Table [1](#Tab1){ref-type="table"}. In this cohort, 430 (84.3%) had CS-GNB and 80 (15.7%) had CR-GNB on rectal swab culture. Univariate analysis demonstrated that patients with CS and CR rectal flora were similar except that a history of urinary tract infection was more common in CR patients (*p* = 0.004). Similar results were observed in the per-protocol population. (Data not shown).Table 1Demographics and clinical characteristics of the intent to treat study population stratified by ciprofloxacin susceptibility statusCiprofloxacin-susceptible\
*N* = 430 (84.3%)Ciprofloxacin-resistant\
*N* = 80 (15.7%)All\
*N* = 510*P* valueDemographics Age, mean +/− SD, (range), years62.7 ± 9.1 (33--88)61.6 ± 7.6 (42--77)62.5 ± 8.9 (33--88)0.323 Race, n (%)0.101  White324 (75.3)52 (65.0)376 (73.7)  Black68 (15.8)15 (18.8)83 (16.3)  Hispanic21 (4.9)9 (11.2)30 (5.9)  Other17 (4.0)4 (5.0)21 (4.1)Clinical characteristics Reason for biopsy, n (%)0.745  Elevated PSA357 (83.0)66 (82.5)423 (82.9)  Abnormal DRE29 (6.7)4 (5.0)33 (6.5)  Both27 (6.3)5 (6.2)32 (6.3)  Other17 (4.0)5 (6.2)22 (4.3) Biopsy result, n (%)0.848  Negative219 (50.9)38 (47.5)257 (50.4)  Prostate cancer167 (38.8)34 (42.5)201 (39.4)  HGPIN44 (10.2)8 (10.0)52 (10.2) History of urinary tract infection, n (%)0.004  Yes39 (9.1)16 (20.0)55 (10.8)  No382 (88.8)60 (75.0)442 (86.7)  Unknown/missing9 (2.1)4 (5.0)13 (2.5) History of urinary retention; n (%)0.769  Yes33 (7.7)6 (7.5)39 (7.6)  No354 (82.3)64 (80.0)418 (82.0)  Unknown/missing43 (10.0)10 (12.5)53 (10.4) FQ usage in prior 2 years, n (%)0.921  Yes95 (22.1)19 (23.8)114 (22.3)  No225 (52.3)42 (52.5)267 (52.4)  Unknown/missing110 (25.6)19 (23.8)129 (25.3) Hospitalized in prior 1 year; n (%)0.653  Yes42 (9.8)6 (7.5)48 (9.4)  No374 (87.0)73 (91.2)447 (87.7)  Unknown/missing14 (3.3)1 (1.2)15 (2.9) Healthcare worker; n (%)0.728  Yes14 (3.3)2 (2.5)16 (3.1)  No357 (83.0)70 (87.5)427 (83.7)  Unknown/missing59 (13.7)8 (10.0)67 (13.1) Charlson comorbidity score; n (%)0.693  0348 (80.9)68 (85.0)416 (81.6)  116 (3.7)2 (2.5)18 (3.5)  232 (7.4)3 (3.8)35 (6.9)  3--1634 (7.9)7 (8.8)41 (8.0)*Abbreviations: PSA* prostate-specific antigen, *DRE* digital rectal exam, *HGPIN* high-grade prostatic intraepithelial neoplasia, *FQ* fluoroquinolone

Microbiological characteristics {#Sec13}
-------------------------------

Of the 80 patients with CR-GNB, 76 (95%) harbored *Escherichia coli*, 2 (2.6%) *Pseudomonas aeruginosa*, 1 (1.2%) *Citrobacter freundii* and 1 (1.2%) *Klebsiella pneumoniae*. The antimicrobial susceptibility profiles of the CR-*E. coli* isolates are shown in Fig. [2](#Fig2){ref-type="fig"}. Using the Centers for Disease Control and Prevention (CDC) definitions \[[@CR22]\] to classify the bacteria, 62 (79.5%) were multidrug-resistant (MDR), 17 (21.5%) were not MDR, and only 12 (15.2%) were resistant to ciprofloxacin alone. Of the MDR *E. coli*, 12 (15.2%) were extended-spectrum beta-lactamase producers (ESBLs). Interestingly, of the 24 patients who underwent two biopsies during the study period, the ciprofloxacin susceptibility status of 23 patients remained the same, while one patient who originally had CR-GNB had CS-GNB on subsequent culture. The antimicrobial prophylaxis regimens received are listed in Table [2](#Tab2){ref-type="table"}. Oral regimens were used for 61 (76.3%) of the 80 patients harboring CR-GNB. Twenty-four patients with CS-GNB received prophylaxis with ciprofloxacin plus another empiric antimicrobial agent; likewise, 2 with CR-GNB received prophylaxis with two non-FQ agents directed by rectal flora susceptibility.Fig. 2Antimicrobial Susceptibility Profile of 76\* Ciprofloxacin-resistant E. coli Isolates. Tmp/smx, Trimethoprim/Sulfamethoxazole. \*Not all isolates were tested for all antimicrobial agents, \*\*Number of isolates tested for this particular antimicrobial agent, \*\*\*Carbapenems tested included imipenem (*n* = 49), meropenem (*n* = 76) Table 2Antimicrobial prophylaxis received versus ciprofloxacin resistance statusDrug received\
*N* = 510Ciprofloxacin-susceptible\
430, (84.3%)Ciprofloxacin-resistant\
80, (16.3%)Amikacin02 (2.5)Aztreonam01 (1.2)Bactrim023 (28.8)Bactrim + Gentamicin01(1.2)Bactrim + Meropenem01 (1.2)Ceftriaxone03 (3.8)Cefuroxime038 (47.5)Ciprofloxacin406 (94.4)0Ciprofloxacin + Amoxicillin3 (0.7)0Ciprofloxacin + Gentamicin21 (4.9)0Ertapenem04 (5.0)Gentamicin07 (8.8)

Infectious complications {#Sec14}
------------------------

The clinical characteristics stratified by infectious outcomes for the ITT and the per-protocol patients are shown in Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}, respectively. In the ITT group, 501 patients (98.2%) did not develop infections, while 9 (1.8%) had clinical infections and 6 (1.2%) of these were culture-proven (CP). In the per-protocol group, 475 patients (98.1%) did not develop infections, while 9 (1.9%) had clinical infections and again, 6 (1.2%) of these were CP. No statistically significant differences were observed in the demographics, clinical characteristics, or infection rate of the ITT versus the per-protocol analysis.Table 3Demographic and clinical characteristics stratified by infection outcomes in the intent to treat study populationNo infection\
*N* = 501 (98.2%)Infection\
*N* = 9 (1.8%)All\
*N* = 510*P* valueDemographics Age, mean +/− SD, (range), years62.5 ± 8.9 (33--88)63.4 ± 6.5 (48--71)62.5 ± 8.9 (33--88)0.75 Race, n (%)1.0  White368 (73.5)8 (88.9)376 (73.7)  Black82 (16.4)1 (11.1)83 (16.3)  Hispanic30 (6.0)0 (0.0)30 (5.9)  Other21 (4.2)0 (0.0)21 (4.1)Clinical characteristics Biopsy result, n (%)0.611  Negative253 (50.5)4 (44.4)257 (50.4)  Prostate cancer196 (39.1)5 (55.6)201 (39.4)  HGPIN52 (10.4)0 (0.0)52 (10.2) History of urinary tract infection, n (%)0.029  Yes52 (10.4)3 (33.3)55 (10.8)  No437 (87.2)5 (55.6)442 (86.7)  Unknown/missing12 (2.4)1 (11.1)13 (2.5) History of urinary retention; n (%)0.499  Yes38 (7.6)1 (11.1)39 (7.6)  No410 (81.8)8 (88.9)418 (82.0)  Unknown/missing53 (10.6)0 (0.0)53 (10.4) FQ usage in prior 2 years, n (%)0.678  Yes111 (22.2)3 (33.3)114 (22.3)  No263 (52.5)4 (44.4)267 (52.4)  Unknown/missing127 (25.3)2 (22.2)129 (25.3) Hospitalized in prior 1 year; n (%)0.400  Yes46 (9.2)2 (22.2)48 (9.4)  No440 (87.8)7 (77.8)447 (87.7)  Unknown/missing15 (3.0)0 (0.0)15 (2.9) Healthcare worker; n (%)0.713  Yes16 (3.2)0 (0.0)16 (3.1)  No418 (83.4)9 (100)427 (83.7)  Unknown/missing67 (13.4)0 (0.0)67 (13.1) Charlson comorbidity score; n (%)0.139  0410 (81.8)6 (66.7)416 (81.6)  117 (3.4)1 (11.1)18 (3.5)  235 (7.0)0 (0.0)35 (6.9)  3--1639 (7.8)2 (22.2)41 (8.0)*Abbreviations: HGPIN* high-grade prostatic intraepithelial neoplasia, *FQ* fluoroquinolone Table 4Demographics and clinical characteristics stratified by infection outcomes in the per-protocol study populationNo infection\
*N* = 475 (98.1%)Infection\
*N* = 9 (1.9%)All\
*N* = 484*P* valueDemographics Age, mean ± SD, (range), years62.5 ± 9.0 (33--88)63.4 ± 6.5 (48--71)62.5 ± 9.0 (48--71)0.75 Race, n (%)1.0  White351 (73.9)8 (88.9)359 (74.2)  Black77 (16.2)1 (11.1)78 (16.1)  Hispanic27 (5.7)0 (0.0)27 (5.6)  Other20 (4.2)0 (0.0)20 (4.1)Clinical characteristics Biopsy result, n (%)0.609  Negative241 (50.7)4 (44.4)245 (50.6)  Prostate cancer185 (38.9)5 (55.6)190 (39.3)  HGPIN49 (10.3)0 (0.0)49 (10.1) History of urinary tract infection, n (%)0.029  Yes50 (10.5)3 (33.3)53 (10.9)  No414 (87.2)5 (55.6)419 (86.6)  Unknown/missing11 (2.3)1 (11.1)12 (2.5) History of urinary retention; n (%)0.511  Yes38 (8.0)1 (11.1)39 (8.1)  No387 (81.5)8 (88.9)395 (81.6)  Unknown/missing50 (10.5)0 (0.0)50 (10.3) FQ usage in prior 2 years, n (%)0.681  Yes109 (22.9)3 (33.3)112 (23.1)  No254 (53.5)4 (44.4)258 (53.3)  Unknown/Missing112 (23.6)2 (22.2)114 (23.6) Hospitalized in prior 1 year; n (%)0.388  Yes44 (9.3)2 (22.2)46 (9.5)  No418 (88.0)7 (77.8)425 (87.8)  Unknown/missing13 (2.7)0 (0.0)13 (2.7) Healthcare worker; n (%)0.710  Yes16 (3.4)0 (0.0)16 (3.3)  No406 (85.5)9 (100.0)415 (85.7)  Unknown/missing53 (11.2)0 (0.0)53 (11.0) Charlson comorbidity score; n (%)0.144  0387 (81.5)6 (66.7)393 (81.2)  116 (3.4)1 (11.1)17 (3.5)  235 (7.4)0 (0.0)35 (7.2)  3--1637 (7.8)2 (22.2)39 (8.1)*Abbreviations: HGPIN* high-grade prostatic intraepithelial neoplasia, *FQ* fluoroquinolone

The infection outcomes stratified by CS or CR status for the ITT and per-protocol groups are shown in Table [5](#Tab5){ref-type="table"}. All infections occurred in the per-protocol patients. There was no statistically significant difference in the rate of infections (CS = 1.5%; CR =3.9%; *p* = 0.337) between the two groups. Additionally, there were no statistically significant differences in the efficacy of the prophylactic regimens used. (Data not shown).Table 5Infectious outcomes of the intent to treat and per-protocol study populations stratified by ciprofloxacin susceptibility statusCiprofloxacin-susceptibleCiprofloxacin-resistantAll*P* valueIntent to Treat*N* (%) = 430 (84.3)*N* (%) = 80 (15.7)*N* (%) = 510Any infection n, (%), 95% CI6, (1.4), 0.5--3.83, (3.8), 0.8--10.69 (1.8) 0.8--3.30.314 No/Yes (n/n; %/%)424/6 (98.6/1.4)77/3 (96.2/3.8)501/9 (98.2/1.8) Type of infection; n (%)0.277  None424 (98.6)77 (96.2)501 (98.2)  Uncomplicated UTI3 (0.7)2 (2.5)5 (1.0)  Complicated UTI1 (0.2)0 (0.0)1 (0.2)  Urosepsis2 (0.5)1 (1.3)3 (0.6)Per Protocol*N* = 406 (83.9%)*N* = 78 (16.1%)*N* = 484Any infection n, (%), 95% CI6, (1.5), 0.5--3.03, (3.9), 0.8--10.8)9, (1.9), 0.9--3.50.337 No/Yes (n/n; %/%)400/6 (98.5/1.5)75/3 (96.1/3.9)475/9 (98.1/1.9) Type of infection; n (%)0.288  None400 (98.5)75 (96.1)475 (98.1)  Uncomplicated UTI3 (0.7)2 (2.6)5 (1.0)  Complicated UTI1 (0.2)0 (0.0)1 (0.2)  Urosepsis2 (0.5)1 (1.3)3 (0.6)*Abbreviations: UTI* urinary tract infection

The characteristics of the 9 patients who developed infectious complications are shown in Table [6](#Tab6){ref-type="table"}. All infections occurred in patients who received single drug targeted prophylaxis. Infectious complications occurred in 6 (66.7%) patients within 7 days and in 3 (33.3%) patients at 8, 11, and 13 days, respectively.Table 6Characteristics of patients with infections post-TRUSPType of infectionAge, Charlson scoreCiproAbx prophyDays to infxnPositive culture? Culture siteOrganism; susceptibilitiesTreatmentHospitalized? If so, LOSResolvedCommentsUncomplicated UTI65, 1SCipro1Yes; Urine*E. coli*: S cipro \</= 1; R amp, pip, tcn, tmp/smx, gent, tobraCeftriaxone; cefuroximeNo; only seen in ED and dischargedYesCipro failureUncomplicated UTI64, 0Rtmp/smx2Yes; UrineE. coli: R tmp/smxCiprofloxacinNoYesFailure of screening or increasing organism resistanceUncomplicated UTI62, 5RAmikacin13Yes; UrineE. coli: S amikacin; R amp, amp/sul, cipro, tmp/smx, and ESBLUnknownNoYesAmikacin failureUncomplicated UTI69, 0SCipro1NoN/ANo antibioticsNoYesClinical diagnosisUncomplicated UTI64, 0SCipro8Yes; Urine*K. pneumoniae*: R ampTmp/smxNoYesCipro failureComplicated UTI71, 4SCipro6Yes; Urine*P. mirabilis*: I cipro 2; R amp, nitro, tmp/smx:Piperacillin; ceftriaxone; cefiximeNo; 1 day of observationYesFailure of screening or increasing organism resistanceUrosepsis66, 0SCipro11NoN/ACeftriaxone; cefuroximeYes; 2 daysYesClinical diagnosisUrosepsis62, 0Rtmp/smx6NoN/APiperacillin; meropenem; cefiximeYes; 5 daysYesClinical diagnosisUrosepsis48, 0SCipro1Yes;\
Urine/bloodE. coli: ESBL plus I nitro, R cipro \>4Vancomycin and meropenem; Tmp/smxYes; 3 daysYesFailure of screening or increasing organism resistance*Abbreviations: Abx prophy* antibiotic prophylaxis, *Amp* Ampicillin, *Amp/sul* Ampicillin-Sulbactam, *Cipro* Ciprofloxacin, *E. coli Escherichia coli*, *ED* emergency department, *ESBL* extended-spectrum beta-lactamases, *Gent* Gentamicin, *I* intermediate, *Infxn* infection, *K. pneumoniae Klebsiella pneumoniae*, *LOS* length of stay, *Nitro* Nitrofurantoin, *P. mirabilis* Proteus mirabilis, *Pip* Piperacillin, *R* resistant, *S* sensitive, *Tcn* Tetracycline, *Tmp/smx* Trimethoprim/Sulfamethoxazole, *Tobra* Tobramycin, *UTI* Urinary tract infection

The 5 patients with uncomplicated UTIs were managed as outpatients, 4 with and 1 without antimicrobial therapy; those with complicated UTIs or sepsis were managed with antimicrobial therapy as inpatients for 1--5 (mean 2.6) days.

All patients recovered without sequelae. There were no drug-related adverse events. None of the 26 patients in the ITT group who received augmented prophylaxis developed infectious complications.

Three (33.3%) of the 9 patients with infections were culture negative. Of the 6 patients with positive cultures, 3 (2 ciprofloxacin and 1 amikacin) were prophylaxis failures, i.e. the infecting bacteria were susceptible to the prophylactic drug they received. One patient who received ciprofloxacin was infected with bacteria with a MIC that was intermediate to ciprofloxacin and 2 patients, one who received trimethoprim/sulfamethoxazole and one who received ciprofloxacin, broke through with organisms fully resistant to these drugs.

Discussion {#Sec15}
==========

With empiric single drug antimicrobial prophylaxis for TRUSP the hospitalization rate for infections is 0 to 6.3%.^2^ Two approaches to address this have been developed. Empiric augmented prophylaxis has shown initially promising results. However, it is often influenced by local hospital antibiograms, fails to assess the rectal source of the post-biopsy infections, and its use will likely be directly related to increasing antimicrobial resistance. Alternatively, rectal swab cultures can 1) determine the population of fluoroquinolone-resistant (FQR)-GNB in the rectal flora, 2) identify specific patients with FQ -GNB and 3) guide targeted single drug and augmented prophylaxis \[[@CR7], [@CR14], [@CR16], [@CR19], [@CR23], [@CR24]\]. The presence of FQ-R bacteria in the rectal flora constitutes a five-fold increase in the rate and potential severity of post-biopsy infections in patients receiving empiric fluoroquinolone prophylaxis \[[@CR25]\]. This finding supports the utilization of pre-biopsy rectal cultures to identify patients at increased risk and to select targeted prophylaxis that is most likely to be effective. These principles were supported by this prospective cohort study, which showed a very low, i.e. 0.6%, sepsis rate and equivalent infectious complication rates among patients with CR-GNB or CS-GNB rectal flora who received targeted prophylaxis per our protocol.

In our study, the FQ resistance rate was 15.7%. We agree with Van Besien et al. \[[@CR25]\] who stated that the benefit of targeted prophylaxis depends on local FQ-R prevalence rates. A randomized, blinded trial would subject the approximately 20% of patients who harbor FQ-R flora and receive FQ prophylaxis to the known 5-fold higher risk of infectious complications \[[@CR25]\]. Similarly, empiric augmented prophylaxis could also subject patients to ineffective antimicrobial prophylaxis. For example, gentamicin is frequently used for augmented prophylaxis, but gentamicin resistance was present in 20% of the bacteria isolated from our patients with CR-GNB rectal flora (Fig. [2](#Fig2){ref-type="fig"}).

Our infectious complication rate in the per-protocol patients of 1.9% improved upon the 2.6% infection rate prior to the introduction of this protocol \[[@CR14]\]. We used very stringent criteria: inclusion of all patients with symptoms of urinary tract infection irrespective of urine or blood cultures and phone screening at 7-and 30-days. Indeed, of the 9 patients identified, 3 had negative cultures before antimicrobial therapy was initiated and 3 were negative at 7 days but positive within 30 days. More importantly, only 4 (0.8%) had significant clinical infections and only 2 were culture-proven, febrile UTI (0.2%) and sepsis (0.2%).

Of the 9 patients with infections, only 3 had prior exposure to fluoroquinolones, a rate similar to those who did not become infected. Of the 6 patients with positive cultures, 3 were prophylaxis failures, i.e. the infecting bacteria was susceptible to the prophylactic drug given, (ciprofloxacin 2, and amikacin 1). Since all of these patients received their prophylaxis per protocol, we cannot implicate noncompliance of the patient or medical error. Breakthrough infections were probably due to excessive inoculum at the time of biopsy and/or an unrecognized host risk factor(s). Three patients were infected with bacteria with antimicrobial susceptibility breakpoints that showed resistance whereas the pre-biopsy rectal bacteria were susceptible. This could be due to sampling error of the rectal flora, lack of detection on the selective media or increasing antimicrobial resistance between the time of the culture and the biopsy. Although incorporating a lower concentration of ciprofloxacin into the screening media may have rendered the two rectal cultures with intermediate susceptibility ciprofloxacin-resistant, this extremely low incidence in our opinion would not support lowering the ciprofloxacin concentration in the screening media in our population.

Of the 6 culture-proven infections, the bacteria were multidrug resistant in 5, and of these, 2 were ESBLs. Williamson et al. noted similar results \[[@CR26]\]. We identified trends in risk factors, e.g. history of UTI, however the incidence of infections was too low to achieve statistical significance \[[@CR12], [@CR24], [@CR27]--[@CR29]\].

This study is limited in that it was a single institution study and, for ethical reasons, was not blinded or controlled. Erectile dysfunction, a potential complication of TRUSP, was not evaluated, but it may occur as a result of inflammation induced by infection \[[@CR30]\]. Thus, targeted prophylaxis could have other indirect benefits. Larger, multicenter studies are necessary to study this approach and its generalizability.

Additionally, this study does not claim superiority to empiric augmented prophylaxis in terms of infection reduction. However, it is likely that antimicrobial prophylaxis based on real time sensitivity data will be more durable and will likely outperform empiric prophylaxis as bacterial resistance inevitably increases. It is possible that more extended use of augmented prophylaxis or use of multiday therapy \[[@CR16], [@CR29], [@CR31], [@CR32]\] would have reduced our infectious complications further, but adherence to the guidelines of antimicrobial stewardship favors limited, single drug targeted prophylaxis for most patients.

Conclusions {#Sec16}
===========

Targeted antimicrobial prophylaxis achieved a low rate of infectious complications in patients with CS- or CR- GNB rectal flora, limited morbidity and no sequelae. These results suggest that this individualized method of prophylaxis may be widely applied. Further studies are needed to explore reasons for targeted prophylaxis failure and to determine comparative efficacy of non-ciprofloxacin-containing targeted prophylaxis regimens.
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Additional file 1:Pre-biopsy Questionnaire. This supplementary document details the data obtained from participants prior to biopsy to collect demographic information and to evaluate risk factors for infection. (DOCX 13 kb) Additional file 2:Surveillance for Ciprofloxacin Resistant Enterobacteriaceae using MacConkey Agar with 1 μg/ml Ciprofloxacin. This supplementary document describes the protocol used for rectal swab culture in this study. (DOCX 16 kb) Additional file 3:Antimicrobial Recommendations for TRUSP Prophylaxis. This supplementary document describes the protocol for selection of prophylactic antimicrobial agents. (DOCX 16 kb) Additional file 4:Post-biopsy Phone Questionnaire. This supplementary document lists the questions asked of participants via phone following biopsy to assess for infectious complications and adverse drug reactions. (DOCX 71 kb)

Abx prophy

:   Antibiotic prophylaxis

Amp

:   Ampicillin

Amp/sul

:   Ampicillin-Sulbactam

AUA

:   American Urological Association

Cipro

:   Ciprofloxacin

CLSI

:   Clinical Laboratory Standards Institute

CP

:   Culture proven

CR-GNB

:   Ciprofloxacin-resistant gram-negative bacteria

CS-GNB

:   Ciprofloxacin-sensitive gram-negative bacteria

DRE

:   Digital rectal exam

*E. coli*

:   *Escherichia coli*

ED

:   Emergency department

ESBL

:   Extended-spectrum beta-lactamases

FQ

:   Fluoroquinolone

FQ-R

:   Fluoroquinolone-resistant

Gent

:   Gentamicin

GNR

:   Gram-negative rods

HGPIN

:   High-grade prostatic intraepithelial neoplasia

I

:   Intermediate

Infxn

:   Infection

ITT

:   Intent to treat

K. pneumonia

:   *Klebsiella pneumoniae*

LOS

:   Length of stay

MDR

:   Multi-drug resistant

Nitro

:   Nitrofurantoin

NU

:   Northwestern University

*P. mirabilis*

:   Proteus mirabilis

Pip

:   Piperacillin

PSA

:   Prostate-specific antigen

R

:   Resistant

S

:   Sensitive

Tcn

:   Tetracycline

Tmp/smx

:   Trimethoprim/Sulfamethoxazole

Tobra

:   Tobramycin

TRUSP

:   Transrectal ultrasound guided prostate biopsy

UTI

:   Urinary tract infection

**Electronic supplementary material**

The online version of this article (doi:10.1186/s12879-017-2470-1) contains supplementary material, which is available to authorized users.

The authors would like to thank the research study coordinators and members of the Department of Urology who contributed to this study: Mary Kate Keeter MPH, Annette Kinsella RN, Darlene Marko RN, William Catalona MD, Daniel Dalton MD, John Garnett MD, Stephanie Kielb MD, James Kozlowski MD, Shilajit Kundu MD, William Lin MD, and Joshua Meeks MD/PhD.

Funding {#FPar1}
=======

The State of Illinois Excellence in Academic Medicine (EAM) grant funded this project: STU00059558 EAM-237. Support was provided for data collection, study design and interpretation. The funding body had no influence on these activities.

Availability of data and materials {#FPar2}
==================================

The datasets generated and analyzed during the current study are available from the corresponding author. Potential collaborators or request for data can be submitted to ajschaeffer\@northwestern.edu.

Authors' contributions {#FPar3}
======================

The study was conceived by AJS and TZ. The study was designed by AJS, TZ, JC, MS and CQ. Patient recruitment and study coordination was conducted by KM, RN, TZ, and AJS. Data analysis and interpretation was performed by TZ, JC, AJS, MS and CQ. AJS, TZ, KM and JC drafted the manuscript. All authors read and approved the final manuscript.

Competing interests {#FPar4}
===================

The authors declare that they have no competing interests.

Consent for publication {#FPar5}
=======================

Not applicable.

Ethics approval and consent to participate {#FPar6}
==========================================

The Northwestern University Institutional Review Board approved this study (STU00059558). The clinical trial was registered on [Clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/NCT01659866) (NCT01659866) prior to the start of the study (Registered 9 July 2012. First patient enrolled 1 November 2012). Written informed consent to participate in the study was obtained from all study participants.

Publisher's Note {#FPar7}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
